Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation

Abooshahab, Raziyeh; Gholami, Morteza; Sanoie, Maryam; Azizi, Fereidoun; Hedayati, Mehdi

doi:10.1007/s12020-019-01904-1

Cited by 33 publications

(26 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, Torregrossa et al also did not find this metabolite to be a marker of malignancy 9 . Glutamine is another compound essential for tumor growth, including thyroid cancer 36,44,45 . This metabolite is involved in many biochemical pathways including glutaminolysis.…”

Section: Discussionmentioning

confidence: 99%

Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use of 1H HR MAS NMR spectroscopy

Skorupa

Ciszek

Chmielik

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The purpose of this work was to investigate the distinct and common metabolic features of the malignant and benign thyroid lesions in reference to the non-transformed tissue from the contralateral gland (chronic thyroiditis and colloid goiter). 1H HR MAS NMR spectra of 38 malignant lesions, 32 benign lesions and 112 samples from the non-tumoral tissue (32 from chronic thyroiditis and 80 samples from colloid goiter) were subjected both to multivariate and univariate analysis. The increased succinate, glutamine, glutathione, serine/cysteine, ascorbate, lactate, taurine, threonine, glycine, phosphocholine/glycerophosphocholine and decreased lipids were found in both lesion types in comparison to either colloid goiter or chronic thyroiditis. The elevated glutamate and choline, and reduced citrate and glucose were additionally evident in these lesions in reference to goiter, while the increased myo-inositol—in comparison to thyroiditis. The malignant lesions were characterized by the higher alanine and lysine levels than colloid goiter and thyroiditis, while scyllo-inositol was uniquely increased in the benign lesions (not in cancer) in comparison to both non-tumoral tissue types. Moreover, the benign lesions presented with the unique increase of choline in reference to thyroiditis (not observed in the cancerous tissue). The metabolic heterogeneity of the non-tumoral tissue should be considered in the analysis of metabolic reprogramming in the thyroid lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use of 1H HR MAS NMR spectroscopy

Skorupa

Ciszek

Chmielik

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Such a profile describes the biochemical events occurring in an organism and it reflects the complex interactions among age, sex, gene transcription, protein expression, physio-pathological conditions, including gut microbiome activity and environment effects [ 20 , 21 ]. These features make metabolomics an important tool to assess the patients’ phenotypes and it has already been widely used to identify diagnostic cancer signatures and prognostic biomarkers [ 22 , 23 , 24 , 25 ]. However, only a few metabolomics studies have been reported for sarcoma and they mainly regard in vitro investigations [ 26 , 27 ]; those performed in a clinical setting were focused on specific sarcoma subgroups [ 28 , 29 , 30 ] and limited only to gemcitabine treatment [ 31 ].…”

Section: Introductionmentioning

confidence: 99%

Integration of Serum Metabolomics into Clinical Assessment to Improve Outcome Prediction of Metastatic Soft Tissue Sarcoma Patients Treated with Trabectedin

Miolo

Gregorio

Saorin

et al. 2020

Cancers

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers with few diagnostic or prognostic biomarkers. This metabolomics study aimed to identify new serum prognostic biomarkers to improve the prediction of overall survival in patients with metastatic STS. The study enrolled 24 patients treated with the same trabectedin regimen. The baseline serum metabolomics profile, targeted to 68 metabolites encompassing amino acids and bile acids pathways, was quantified by liquid chromatography-tandem mass spectrometry. Correlations between individual metabolomics profiles and overall survival were examined and a risk model to predict survival was built by Cox multivariate regression. The median overall survival of the studied patients was 13.0 months (95% CI, 5.6–23.5). Among all the metabolites investigated, only citrulline and histidine correlated significantly with overall survival. The best Cox risk prediction model obtained integrating metabolomics and clinical data, included citrulline, hemoglobin and patients’ performance status score. It allowed to distinguish patients into a high-risk group with a low median overall survival of 2.1 months and a low- to moderate-risk group with a median overall survival of 19.1 months (p < 0.0001). The results of this metabolomics translation study indicate that citrulline, an amino acid belonging to the arginine metabolism, represents an important metabolic signature that may contribute to explain the high inter-patients overall survival variability of STS patients. The risk prediction model based on baseline serum citrulline, hemoglobin and performance status may represent a new prognostic tool for the early classification of patients with metastatic STS, according to their overall survival expectancy.

show abstract

“…2021, 22, 4196 2 of 12 TC is the most common endocrine cancer. Its incidence has been growing in recent years, especially in females, suggesting that female hormones may be involved in pathogenesis [1]. There are various types of TC, which are classified considering the cell of origin and histological characteristics into two main groups: a) well-differentiated, including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and Hürthle cell carcinoma; and b) poorly differentiated (PDTCs), such as anaplastic/undifferentiated thyroid carcinoma (ATC) and medullary thyroid cancer (MTC).…”

Section: Introduction 1thyroid Tumorsmentioning

confidence: 99%

Molecular Chaperones and Thyroid Cancer

Paladino

Vitale

Santonocito

et al. 2021

IJMS

View full text Add to dashboard Cite

Thyroid cancers are the most common of the endocrine system malignancies and progress must be made in the areas of differential diagnosis and treatment to improve patient management. Advances in the understanding of carcinogenic mechanisms have occurred in various fronts, including studies of the chaperone system (CS). Components of the CS are found to be quantitatively increased or decreased, and some correlations have been established between the quantitative changes and tumor type, prognosis, and response to treatment. These correlations provide the basis for identifying distinctive patterns useful in differential diagnosis and for planning experiments aiming at elucidating the role of the CS in tumorigenesis. Here, we discuss studies of the CS components in various thyroid cancers (TC). The chaperones belonging to the families of the small heat-shock proteins Hsp70 and Hsp90 and the chaperonin of Group I, Hsp60, have been quantified mostly by immunohistochemistry and Western blot in tumor and normal control tissues and in extracellular vesicles. Distinctive differences were revealed between the various thyroid tumor types. The most frequent finding was an increase in the chaperones, which can be attributed to the augmented need for chaperones the tumor cells have because of their accelerated metabolism, growth, and division rate. Thus, chaperones help the tumor cell rather than protect the patient, exemplifying chaperonopathies by mistake or collaborationism. This highlights the need for research on chaperonotherapy, namely the development of means to eliminate/inhibit pathogenic chaperones.

show abstract

Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation

Cited by 33 publications

References 114 publications

Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use of 1H HR MAS NMR spectroscopy

Shared and unique metabolic features of the malignant and benign thyroid lesions determined with use of 1H HR MAS NMR spectroscopy

Integration of Serum Metabolomics into Clinical Assessment to Improve Outcome Prediction of Metastatic Soft Tissue Sarcoma Patients Treated with Trabectedin

Molecular Chaperones and Thyroid Cancer

Contact Info

Product

Resources

About